[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648122":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":28,"centralContacts":34,"locations":40,"responsibleParty":124,"collaborators":28,"id":126,"slug":127,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":28,"eligibilityCriteria":132,"healthyVolunteers":128,"sex":133,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":28,"studyType":139,"phases":140,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":43,"whyStopped":28,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":161},{"fullName":5,"class":6},"Axsome Therapeutics, Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Solriamfetol Dose A","EXPERIMENTAL","Up to 6 weeks",[13],"Drug: Solriamfetol Dose A",{"label":15,"type":10,"description":11,"interventionNames":16},"Solriamfetol Dose B",[17],"Drug: Solriamfetol Dose B",{"label":19,"type":20,"description":11,"interventionNames":21},"Placebo","PLACEBO_COMPARATOR",[22],"Drug: Placebo",[24,29,31],{"type":25,"name":9,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Solriamfetol capsules, taken once daily",[9],null,{"type":25,"name":15,"description":26,"armGroupLabels":30,"otherNames":28},[15],{"type":25,"name":19,"description":32,"armGroupLabels":33,"otherNames":28},"Placebo capsules, taken once daily",[19],[35],{"name":36,"role":37,"phone":38,"phoneExt":28,"email":39},"Study Director","CONTACT","929-618-4421","akim@axsome.com",[41,55,64,73,81,89,97,106,115],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":28},"Clinical Research Site","RECRUITING","Dothan","Alabama","36303","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-85.39049,31.22323,{"lat":53,"lon":52},{"facility":42,"status":43,"city":56,"state":57,"zip":58,"country":47,"countryCode":48,"cosmosGeoPoint":59,"geoPoint":63,"contacts":28},"Little Rock","Arkansas","72211",{"type":50,"coordinates":60},[61,62],-92.28959,34.74648,{"lat":62,"lon":61},{"facility":42,"status":43,"city":65,"state":66,"zip":67,"country":47,"countryCode":48,"cosmosGeoPoint":68,"geoPoint":72,"contacts":28},"Coral Gables","Florida","33146",{"type":50,"coordinates":69},[70,71],-80.26838,25.72149,{"lat":71,"lon":70},{"facility":42,"status":43,"city":74,"state":66,"zip":75,"country":47,"countryCode":48,"cosmosGeoPoint":76,"geoPoint":80,"contacts":28},"Jacksonville","32256",{"type":50,"coordinates":77},[78,79],-81.65565,30.33218,{"lat":79,"lon":78},{"facility":42,"status":43,"city":82,"state":66,"zip":83,"country":47,"countryCode":48,"cosmosGeoPoint":84,"geoPoint":88,"contacts":28},"Maitland","32751",{"type":50,"coordinates":85},[86,87],-81.36312,28.62778,{"lat":87,"lon":86},{"facility":42,"status":43,"city":90,"state":66,"zip":91,"country":47,"countryCode":48,"cosmosGeoPoint":92,"geoPoint":96,"contacts":28},"Orlando","32801",{"type":50,"coordinates":93},[94,95],-81.37924,28.53834,{"lat":95,"lon":94},{"facility":42,"status":43,"city":98,"state":99,"zip":100,"country":47,"countryCode":48,"cosmosGeoPoint":101,"geoPoint":105,"contacts":28},"Bardstown","Kentucky","40004",{"type":50,"coordinates":102},[103,104],-85.4669,37.80923,{"lat":104,"lon":103},{"facility":42,"status":43,"city":107,"state":108,"zip":109,"country":47,"countryCode":48,"cosmosGeoPoint":110,"geoPoint":114,"contacts":28},"Memphis","Tennessee","38119",{"type":50,"coordinates":111},[112,113],-90.04898,35.14953,{"lat":113,"lon":112},{"facility":42,"status":43,"city":116,"state":117,"zip":118,"country":47,"countryCode":48,"cosmosGeoPoint":119,"geoPoint":123,"contacts":28},"Austin","Texas","78759",{"type":50,"coordinates":120},[121,122],-97.74306,30.26715,{"lat":122,"lon":121},{"type":125,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100648122","phase-3-a-study-to-assess-the-efficacy-and-safety-of-solriamfetol-in-children-with-adhd-100648122",false,"NCT07717879","A Study to Assess the Efficacy and Safety of Solriamfetol in Children With ADHD","A Phase 3, Randomized, 6-Week, Double-blind, Placebo-controlled Trial of Solriamfetol in Children Aged 6 to \u003C12 Years With Attention Deficit Hyperactivity Disorder (ADHD)","Inclusion Criteria:\n\n* Male or female, aged 6 to \\\u003C12 years.\n* Primary diagnosis of ADHD according to DSM-5 criteria.\n* Has parents\u002Flegal guardians provide written informed consent and has child provide written informed assent to participate in the study before the conduct of any study procedures.\n\nExclusion Criteria:\n\n* Unable to comply with study procedures.\n* Medically inappropriate for study participation in the opinion of the investigator.","ALL","6 Years","11 Years",{"count":137,"type":138},468,"ESTIMATED","INTERVENTIONAL",[141],"PHASE3","This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in children aged 6 to \\\u003C12 years with ADHD.",[144],"ADHD",[146,144,147,148,149,150,151],"Attention deficit hyperactivity disorder","Sunosi","Solriamfetol","Axsome","Non-stimulant therapy","Dopamine norepinephrine reuptake inhibitor","2026-07-16",{"date":154,"type":155},"2026-07-21","ACTUAL",{"date":157,"type":155},"2026-07-06",{"date":159,"type":138},"2028-06-30",{"name":5,"class":6},9]